Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients.
In response to the ever-growing demand for expert advice on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines Task Forces have developed consensus statements for genitourinary malignancies (renal and prostate carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia). An update of the melanoma consensus statement and new guidelines for bladder and lung cancers are also underway.
Click here for a complete listing of the guidelines and links to view.
SITC is the first and only organization dedicated to cancer immunotherapy to be accepted as a formal member of the Commission on Cancer (CoC), a program of the American College of Surgeons.
The CoC is the nation’s leading accreditation body for cancer care and has established a strong partnership approach to defining and measuring quality as it relates to managing patients with cancer. Today, more than 80 percent of Americans with cancer will seek treatment at a CoC accredited facility.
SITC represents leaders of the field of cancer immunotherapy, to help establish and implement immunotherapy at CoC-accredited institutions and develop mechanisms for collecting data and educating healthcare providers on the optimal way to deliver immunotherapy. SITC Immediate Past President, Howard Kaufman, MD, FACS, of the Rutgers Cancer Institute of New Jersey, serves as SITC’s official liaison to the Commission.
SITC has been a key collaborator in the development of the Foundation for the Accreditation of Cellular Therapy (FACT) Standards for Immune Effector Cell Administration.Marcela Maus, MD, PhD of Harvard Medical School serves as SITC’s official liaison to the FACT CAR-T Cell Task Force.
SITC provided formal comments to the FACT draft of the 1st edition FACT Standards for Immune Effector Cell Administration. These standards are intended to promote quality in the administration of immune effector cells and will be incorporated into a voluntary FACT accreditation in this field.
Click here to download "Standards for Immune Effector Cell Administration".
From Bedside to Bench and Back Again | Boston on September 26-27, 2017 ------------------------------ Joseph Murphy PhD Director Charles River Laboratories Quincy MA ----------------------------
Regarding lymphatic endothelial cell-related cancer and post-transplant recipients. Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) evades immune killing of tumor cells by relying on its immunomodulatory viral antigens. Organ donors in high seroprevalence ...
There is likely an unpublished cohort of patients throughout the world who were treated with ipilimumab prior to the introduction of nivolumab/ipilimumab combination and achieved an either complete remission or partial remission. These patients then ...
The case report presented here on advanced melanoma, in an elderly patient on page 810, indicates that despite of lack of prior ipilimumab treatment it cannot be excluded that subsequent observed astonishing treatment with nivolumab can partially be due ...
An article of Larking et al published in JCO 2017 showed evidence of the CheckMate 037 in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy, in which they conclude that - and I quote- : "nivolumab treatment after ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org